15-min delayed · Sep 2, 8:00 AM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Crinetics Pharmaceuticals Inc, 7 rate it Buy or better, 8 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $84.00 to $95.00, so the covering firms are broadly aligned. The average target of $86.13 sits 1% above the current $84.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.07 next quarter toward $-4.01 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Moderate Buy
Strong Buy00%
Buy747%
Hold853%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Crinetics Pharmaceuticals Inc.
As of Sep, 4 of 12 firms rate CRNX a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRNX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.07
Range $-1.25 – $-0.80 · 8 analysts · -17% YoY
Next period, 8 analysts expect Crinetics Pharmaceuticals Inc to earn $-1.07 a share (range $-1.25 – $-0.80), versus $-1.29 a year earlier. Full-year consensus is $-4.54, growing to $-4.01 the year after.
REVENUE · NEXT QUARTER
$84.3M
Range $84.3M – $84.3M · 8 analysts · +1268% YoY
Revenue is expected to reach $84.3M (range $84.3M – $84.3M), +1268.5% year-over-year. Full-year consensus is $161.9M, rising to $178.6M next year.
Top analysts covering Crinetics Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRNX.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Hold
No targeton CRNX
Overall win rate
47%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #71
Buy
$52.00-38.8% to target
Overall win rate
53%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #162
Hold
No targeton CRNX
Overall win rate
38%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #188
Hold
No targeton CRNX
Overall win rate
33%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #248
Hold
$85.00+0.1% to target
Overall win rate
35%
+ Follow
CRNX stock forecast FAQ
What is CRNX's average 12-month price target?+
The 6 analysts with a live target average $86.13 for Crinetics Pharmaceuticals Inc over the next 12 months, ranging from a $95.00 high to a $84.00 low.
Is CRNX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 15 analyst ratings, 7 are Buy or Strong Buy, 8 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRNX?+
The Street-high target is $95.00 (Citizens), and the Street-low is $84.00. The average of all 6 active targets is $86.13.
How many Wall Street analysts cover CRNX?+
15 analysts have an active rating on Crinetics Pharmaceuticals Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRNX?+
Among analysts who currently cover CRNX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Hold.
What is Crinetics Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.07 per share (range $-1.25 – $-0.80) across 8 analysts. Full-year EPS is projected at $-4.54, rising to $-4.01 the following year.
How much revenue is Crinetics Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $84.3M (range $84.3M – $84.3M). Full-year revenue is projected at $161.9M, growing to $178.6M next year.
Have analysts been upgrading or downgrading CRNX lately?+
As of Sep, 4 of 12 firms rate CRNX a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRNX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
